Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, characterized by the loss or low expression of estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) and progesterone receptor (PR). Due to the lack of clear therapeutic targets, paclitaxel (PTX)...
Saved in:
Main Authors: | Jia-xin Qiao, Dong-yan Guo, Huan Tian, Zhan-peng Wang, Qiang-qiang Fan, Yuan Tian, Jing Sun, Xiao-fei Zhang, Jun-bo Zou, Jiang-xue Cheng, Fei Luan, Bing-tao Zhai |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Materials Today Bio |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006424004198 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RSL3 induces ferroptosis by activating the NF-κB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel
by: Jialin Yuan, et al.
Published: (2025-01-01) -
Facile fabrication of TPGS-PCL polymeric nanoparticles for paclitaxel delivery to breast cancer: investigation of antiproliferation and apoptosis induction
by: Tong Chen, et al.
Published: (2024-12-01) -
Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival
by: Marieke Schmidt, et al.
Published: (2024-12-01) -
Peptide Aptamer–Paclitaxel Conjugates for Tumor Targeted Therapy
by: Xinyang Shen, et al.
Published: (2024-12-01) -
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
by: Ziqi Chen, et al.
Published: (2025-02-01)